UKUK

UK stem cell debate reopened

20.05.2008

London – “Chimera” embryos may increase pressure on the British parliament for tougher regulations on stem cell research. At the beginning of April, Dr. Lyle Armstrong and colleagues at Newcastle University created embryos from cow eggs with inserted human DNA. The embryos survived for three days. The researchers said the next step was to create embryos that would live for six days for the purpose of harvesting stem cells. The debate in the UK over the hybrid embryos heated up after Catholic leaders attacked the technique in Easter sermons, and Edinburgh’s Cardinal Keith O’Brien called creating animal-human hybrid embryos “Frankenstein science .” The British parliament is currently discussing changes to a 1990 law that governs stem cell research, including the hybrid work. In September 2007, the UK’s Human Fertilisation and Embryology Authority ended eight months of debate by agreeing to allow research into animal-human embryos, but on a case-by-case basis and under regulations limiting authorised projects to those deemed “necessary and desirable.” Four months later, the HFEA approved one-year research licenses for teams of scientists at Kings College London and Newcastle University to carry out research using the embryos, subject to a series of detailed conditions.
The bill is to be formally presented in May to Britain’s lower house of parliament (the House of Commons) for its first reading, when legislation is not usually debated. The Human Fertilisation and Embryology Bill, which has been approved by the upper house (the House of Lords) would explicitly allow research using hybrid embryos like those created by the Newcastle team.

UKUK

02.04.2012

London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...

UKUK

21.03.2012

London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...

UKUK

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...

UKUK

06.03.2012

GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...

UKUK

27.02.2012

London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...

UKUK

08.02.2012

London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...

UKUK

03.02.2012

London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...

UKUK

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-uk/article/uk-stem-cell-debate-reopened.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR268.4%
  • SANTHERA (CH)65.50 CHF81.9%
  • ADDEX (CH)4.01 CHF79.0%

FLOP

  • MERCK KGAA (D)65.21 EUR-48.8%
  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-23.5%

TOP

  • SANTHERA (CH)65.50 CHF3175.0%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR315.2%

FLOP

  • CYTOS (CH)0.28 CHF-91.8%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.7%

No liability assumed, Date: 28.07.2014


Current issue

All issues

Product of the week

Products